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INTRODUCTION 
Urinary tract infections have been neglected by health 
care professionals for a very long time. Urologists, all 
over the world under estimated the clinical importance of 
UTIs until the occurrence of Multi Drug Resistant 
(MDR) uropathogens causing complicated infections. 
The reason being; the more common occurrence of 
uncomplicated UTIs and the fact that it is easily treated 
and cause negligible mortality among patients.
[1]
 
However, recently there has been a tremendous increase 
in complicated cases of UTIs caused by extremely drug 
resistant uropathogens that has restricted the use of 
available antibiotics. It is estimated that over 150 million 
people get infected with UTIs annually worldwide, 
making it one of the most common infectious disease.
[2] 
 
 
Among the nosocomial infections, UTIs contribute to 
40% of the cases.
[3,4]
 Around 13,000 (2.3%) deaths were 
recorded due to UTIs in the U.S in the year 2014. Also 
13% of all the Hospital acquired infections (HAIs) were 
due to UTIs in the U.S.
[5]
 In India, such statistical and 
epidemiological data is not available due to the lack of 
documentations. However, significant increase in cases 
of complicated UTIs and also increase in mortality rates 
have been reported.
[6,7,8]  
 
Recently there has been an enormous report on the 
occurrence of ESBL producing uropathogens across the 
globe. “ESBLs are functionally defined as β-lactamases 
(belonging to Bush's functional group 2be and Ambler 
molecular class A) able to hydrolyze extended-spectrum 
cephalosporins (ceftazidime or cefotaxime) and 
monobactams (aztreonam) at a rate that is equal to or 
higher than 10% of that for benzyl-penicillin and to be 
inhibited by β-lactamase inhibitors, such as clavulanic 
acid, whereas they cannot hydrolyze cephamycins 
(cefoxitin or cefotetan) or carbapenems (imipenem or 
meropenem) efficiently”.[9] 
 
ESBLs confer resistance to penicillins, oxyimino-
cephalosporins as well as to monobactams. They have 
very little activity against cephamycins, carbapenems 
and β-lactamase inhibitors. ESBLs have been observed 
in several members of Enterobacteriaceae (Enterobacter 
spp, Salmonella spp, Proteus spp, Citrobacter spp, M. 
morganii, S.marcescens, S.dysenteriae) as well as in 
P.aeruginosa and A. baumannii.
[10]
 
The transformation of a β-lactamase enzyme to extended 
spectrum β-lactamases usually follows a point mutation 
in the bla gene resulting in changes in amino acid 
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Growing incidences of Extended Spectrum β-lactamases (ESBL) producing pathogens are a global issue. They are 
enzymes capable of hydrolyzing broad spectrum β-lactam antibiotics. In the current study, Phenotypic screening 
of ESBL producers was done from 747 gram negative uropathogens, among which 167 ESBL producers were 
identified. Screening of ESBL producers was done with the help of Antimicrobial Susceptibility Testing, 
Phenotypic Confirmatory Disc Diffusion Test, Double Disc Synergy Test and E- Test.  Determination of minimum 
inhibitory concentration of 3
rd
 generation cephalosporins, highlighted 37 ESBL producers to be either sensitive, or 
exhibit intermediate resistance to ceftazidime, ceftriaxone or cefotaxime. This indicates difficulty in routine ESBL 
detection where MIC is generally carried out as a screening step for ESBL detection. All ESBL producers showed 
presence of plasmid of approximately 50-60 kb in size. Confirmation of ESBL production was done by PCR 
amplification which showed presence of blaTEM (742bp) gene in 156 out of 167 ESBL producers, blaCTX-M (413bp) 
gene in 63/167 and blaAmpC (346bp) gene in 108/167 ESBL producers. Co-production of multiple β-lactamase 
genes was observed in 144/167 isolates. Class 1 and 2 integrons were detected in 51/167 (30.53%) and 
11/167(7.78%) isolates respectively. Hence our study highlighted high prevalence of co-production of β-
lactamases among uropathogens and the inefficiency of MIC as a phenotypic detection method in screening of β-
lactamases. 
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sequences near the enzyme’s active site and therefore 
altered substrate specificity. In addition, alterations in 
enzyme regulation leading to increased enzyme 
production or alteration in outer membrane protein porin 
channels can also contribute to increased resistance.
[11]
 
The numerous β-lactamases are encoded either by the 
chromosomal genes, or by the transferable genes which 
are located on the plasmids, or transposones.
[12] 
Beta-
lactamases and their mutated forms such as ESBLs and 
AmpC β-lactamases represent a major cause of 
multidrug resistance among enteric bacteria. Following 
selective pressure due to widespread use of β-lactam 
antibiotics in clinical practice, genes for β-lactamases 
have evolved at a very rapid pace with over 1300 
unique β-lactamases reported in clinical isolates.[13] 
 
This study will help in understanding the molecular basis 
of spread of antibiotic resistance in Mumbai by giving an 
overview of the most prevalent ESBL genes.  
 
MATERIALS AND METHODS 
Collection of samples from Mumbai city 
A total of 747 gram negative urine sample isolates were 
collected from 3 government tertiary care hospitals, 4 
private hospitals and 8 pathological laboratories situated 
in Mumbai during September 2011- January 2014.  
 
Phenotypic screening and confirmation of ESBL 
producers 
All the isolates showing resistance to 3
rd
 generation 
cephalosporins, viz. ceftazidime, ceftriaxone and 
cefotaxime, were phenotypically tested for ESBL 
production by Double Disk Synergy test (DDST) and 
Phenotypic Confirmatory Disk Diffusion Test (PCDDT) 
and, confirmation of ESBL production was done using 
E-test. A part of this study, including phenotypic 
characterization of 68 ESBL producers has been 
described in a previous study.
[14]
  
 
Determination of Minimum Inhibition Concentration 
The MIC of 3 antibiotics viz. ceftazidime, ceftriaxone 
and cefotaxime were determined against ESBL 
producers using E-strip (Hi Media Laboratories Pvt. 
Ltd.) with a concentration gradient of 0.5-256 mcg/ml. 
Antibiotics susceptibility determination criteria as per 
CLSI guidelines are indicated in Table 1.
[15]
 
 
 
 
 
Table 1: Antibiotic susceptibility criteria of third generation antibiotics indicated by CLSI guidelines. 
Antibiotics Organisms Susceptible Intermediate Resistant 
Ceftazidime 
Enterobacteriaceae ≤4mcg/ml 8mcg/ml ≥16mcg/ml 
P. aeruginosa ≤8mcg/ml 16mcg/ml ≥32mcg/ml 
Ceftriaxone 
Enterobacteriaceae ≤1mcg/ml 2mcg/ml ≥4mcg/ml 
P. aeruginosa ≤8mcg/ml 16-32mcg/ml ≥64mcg/ml 
Cefotaxime 
Enterobacteriaceae ≤8mcg/ml 16-32mcg/ml ≥64mcg/ml 
P. aeruginosa ≤8mcg/ml 16-32mcg/ml ≥64mcg/ml 
 
Extraction of plasmids  
Plasmid extraction was carried out from overnight grown 
ESBL producing uropathogens by SDS method. 
[16] 
The 
extracted plasmids were treated with RNAse (10mcg/ml) 
and then re-precipitated with 0.1 volume of 3M sodium 
acetate (pH 5.2) and two volumes of ethanol. The RNAse 
free plasmids were run on 1.2% agarose gel and 
visualized under UV, using Gel Documentation System 
to check for presence of plasmid DNA.  
 
Amplification of antibiotic resistant genes by PCR 
Amplification reactions were performed in a 25µl 
reaction mixture volume, containing 2.5µl of 10X PCR 
reaction buffer, 1.5µl (1.5mM) MgCl2, 0.5µl (200µM) 
deoxy-nucleotide triphosphate-mix (dNTPs), 1µl (10pM) 
forward as well as reverse primers (mentioned in Table 
2) and 1µl (3U/ml) of the Taq DNA polymerase 
(Bangalore Genie TM, India). The plasmid DNA (1µl) 
extracted from the ESBL producers were used as 
template and the reaction volume was made up to 25µl 
using sterile double distilled water. The reaction mixture 
was subjected to PCR amplification using a MyCycler 
DNA thermal cycler (Eppendorf). The resultant PCR 
products were analyzed by agarose gel- electrophoresis 
using a 2% agarose gel prepared in TAE (Tris-Acetate-
EDTA) buffer, containing 5µl ethidium bromide 
(5mg/ml).
[16] 
A molecular weight marker (100bp DNA 
ladder) was also included in the gel to confirm the 
amplicon size. All results were documented using a Gel 
Documentation System post- electrophoresis. 
 
 
Table 2: List of primers used in the study. 
Target Primer name Primer sequence 
Annealing 
temperature (°C) 
Amplicon 
size 
blaTEM 
TEM-F 5’-ggt gaa agt aaa aga tgc tg-3’ 
54 742 bp 
TEM-R 5’-acc aat gct taa tca gtg ag-3’ 
blaSHV 
SHV-F 5’-atg cgt tat att cgc ctg tgt a-3’ 
63 725 bp 
SHV-R 5’-tta gcg ttg cca gtg ctc gat c-3’ 
blaCTX-M CTX-M-F 5’-ctt agc gcg gcc gcg cta ca-3’ 65 413 bp 
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CTX-M-R 5’-acc aga atc agc ggc gca cga-3’ 
blaAmp-C 
AmpC-F 5’-aac agc ctc agc agc cgg tta-3’ 
62 346 bp 
AmpC-R 5’-ttc gcc gca atc atc cct agc-3’ 
blaInt-1 
Int1-F 5'-cag tgg aca taa gcc tgt tc-3' 
55 180 bp 
Int1-R 5'-ccc gag gca tag act gta-3' 
blaInt-2 
Int2-F 5'-ttg cga gta tcc ata acc tg-3' 
55 287 bp 
Int2-R 5'-tta cct gca ctg gat taa gc-3' 
 
Analysis of the PCR products 
The PCR amplicons were sequenced by using 
corresponding primers for specific genes listed in Table 
2 and the entire sequence of each gene was compared 
with sequences in the GenBank nucleotide database 
using the blast software available at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. Sequencing of the 
PCR amplicons was carried out at Sci. Genomics Pvt. 
Ltd, Cochin, Kerela, India.  
 
RESULTS AND DISCUSSION 
Detection of ESBL producers 
Our previous study reported the prevalence of E. coli and 
K. pneumoniae among total isolated uropathogens (Table 
3) which was found to be 59.57% and 16.19% 
respectively.
[17]
 
 
Table 3: Total uropathogens isolated from Mumbai. 
Pathogens 
Total no. of 
isolates 
ESBL 
producer 
E. coli 445 106 
K. pneumonia 121 25 
P. mirabilis 44 4 
P. vulgaris 15 3 
P. aeruginosa 67 15 
C. amalonaticus 7 1 
C. diversus 37 12 
E. aerogenes 1 1 
E. cloacae 1 - 
E. fecalis 1 - 
M. morganii 4 - 
A.baumanii 4 - 
Total 747 167 
Determination of MIC 
The MIC values of 3
rd
 generation cephalosporins against 
ESBL producers are indicated in Table 4. Determination 
of MIC by E-test method showed 161/167 isolates to be 
resistant to ceftriaxone. Resistance to ceftazidime and 
cefotaxime was also observed among 150/167 and 
153/167 ESBL producers respectively. Also, among the 
ESBL producers, 12/167 isolates showed intermediate 
resistance and 25/167 isolates showed sensitivity towards 
ceftazidime, cefotaxime and/or ceftriaxone.  
 
This indicates that ESBL production may not be 
associated with complete resistance to cephalosporin 
antibiotic; moderately resistant as well as sensitive 
strains may also be potential ESBL producers. In 
addition, almost all of the isolates resistant to cefotaxime 
and ceftriaxone showed extremely high MIC of 
>256mcg/ml. However such high degree of resistance 
was observed in comparatively few (i.e 45) ceftazidime 
resistant isolates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: MIC of 3
rd
 generation antibiotics against ESBL producers. 
Test isolates 
Ceftazidime Cefotaxime Ceftriaxone 
S I R S I R S I R 
E.coli (n=106) 2 9 95 9 2 95 3 - 103 
K.pneumoniae (n=25) 3 1 21 3 - 22 3 - 22 
P.aeruginosa (n=15) - - 15 - - 15 - - 15 
Proteus spp. (n=7) - - 7 - - 7 - - 7 
Citrobacter spp. (n=13) 2 - 11 - - 13 - - 13 
E.aerogenes (n=1) - - 1 - - 1 - - 1 
S- sensitive; I-intermediate; R-resistant. 
 
In the current study, 91.61% and 96.40% isolates were 
found to be resistant to cefotaxime and ceftriaxone 
respectively. Resistance to these antibiotics is mainly 
associated with the expression of CTX-M and CMY-2 
gene respectively.
[18,19] 
However, in certain cases 
presence of multiple β-lactamase genes may also be 
responsible for resistance to cefotaxime as well as 
ceftriaxone. Resistance to ceftriaxone has also been 
observed in E.clocae isolates that showed decreased 
expression of outer membrane proteins of around 37-
38KDa unidentified proteins.
[20]
 Resistance to 
ceftazidime is not associated with the expression of any 
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specific gene. Many genes like CTX-M
[21]
 and Integron 
IBC-2
[22]
 have been shown to be associated with 
resistance to ceftazidime.  
 
Similar results have been reported in another study 
where, screening test result for ESBL production 
revealed that four cefpodoxime sensitive, six cefotaxime 
sensitive, 11 ceftazidime sensitive and 9 aztreonam 
sensitive isolates were ESBL positive on confirmatory 
test.
[23]
 Another study carried out in an ICU in France, 
also reported low level resistance to cephalosporins 
among ESBL producing uropathogens. They further 
confirmed that; although the cephalosporin MICs were in 
the susceptible range, they were substantially higher than 
the MICs for non-ESBL-producing strains at their 
hospital.
[24]
  
 
Unlike all ceftriaxone and cefotaxime resistant isolates, 
only 45/167 (26.9%) ceftazidime resistant isolates 
showed elevated MIC (i.e >256mcg/ml) in our study. In 
another study carried out by Vu and Nikaido, (1985), it 
was observed that the over-production of class C β-
lactamases i.e AmpC were associated with elevated 
resistance to ceftazidime.
[25]
 Queenan et al. (2010) also 
showed increased activity of AmpC β-lactamases in 
ceftazidime resistant mutants.
[26]
 In our study too, perfect 
correlation was observed between the production of 
AmpC β-lactamase and elevated resistance to 
ceftazidime (Data not shown). In another study, AmpC 
over-production has been reported in 88% ceftazidime 
resistant P.aeruginosa.
[27]
  
 
Moreover, restoration of OmpK36 function in porin-
deficient strains of ESBL producing K.pneumoniae 
causes significant decreases in the MICs of ceftazidime, 
indicating a possible relation between loss of this porin 
and elevated MICs of ceftazidime in K.pneumoniae.
[28]
 
In E.coli, loss of either of the OmpC or OmpF porins is 
responsible for resistance to cephalosporins.
[29]
   
 
In our study, 7 ceftazidime sensitive and 10 ceftazidime 
intermediate isolates were found to be ESBL producers. 
The ceftazidime sensitive isolates i.e E.coli (isolate no. 
262, 264), C.diversus (isolate no.124, 644) and 
K.pneumoniae (isolate no. 275, 507, 536) showed their 
MIC in the range of 2-4mcg/ml. Except for E.coli isolate 
262 and 264, all other ceftazidime sensitive isolates 
showed MIC to be >256mcg/ml towards ceftriaxone. 
Also, K.pneumoniae isolate 275 showed sensitivity to 
ceftazidime and cefotaxime but was found to be resistant 
to ceftriaxone (with MIC >256mcg/ml). Higher 
susceptibility to ceftazidime among ESBL producers has 
also been reported by Rao et al. (2014) where 493 
(80.3%) and 486 (79.1%) isolates of ESBL producing 
E.coli were found to be resistant to ceftriaxone and 
cefotaxime respectively.
 
However, only 228 (37.1%) 
isolates showed resistance to ceftazidime.
[30]
 Similar 
observations were noted for ESBL producing K. 
pneumoniae in the same study, where 382 (82.7%) and 
343 (74.2%) isolates showed resistance to ceftriaxone 
and cefotaxime respectively. However, only 253 (54.8%) 
isolates showed resistant to ceftazidime.
[30]
 It has been 
observed that the CTX-M β-lactamases hydrolyze 
ceftazidime with a very low catalytic efficiency. Thus, 
CTX-M β-lactamases may confer high levels of 
resistance to cefotaxime and ceftriaxone but at the same 
time exhibit marginal effect on the MIC of 
ceftazidime.
[18]
 As observed in the current study all the 
above ceftazidime sensitive isolates, except 
K.pneumoniae (isolate no. 275), showed presence of 
CTX-M gene; thus explaining the difference in the MIC 
of the tested 3
rd
 generation cephalosporins. 
 
Amplification of antibiotic resistant genes 
Plasmid DNA obtained from ESBL producing 
uropathogens was used as a template to amplify blaTEM, 
blaCTX-M, blaSHV, blaAmpC, blaInt1 and blaInt2 genes using its 
specific primers listed in table 2. These were seen as 
discreet bands on 2% agarose gels when visualized under 
UV. PCR amplification showed presence of blaTEM 
(742bp) gene in 156 out of 167 (Fig. 1), blaCTX-M (413bp) 
gene in 63/167 (Fig. 2) and blaAmpC (346bp) gene in 
108/167 (Fig. 3) ESBL producers. Co-production of 
multiple β-lactamase genes was observed in 144/167 
(86.22%) isolates. Class 1 (180bp) and 2 (287bp) 
integrons were detected in 51/167 (30.53%) and 
11/167(6.58%) isolates (Fig. 4 and 5) respectively. Co-
production of Class 1 and 2 integrons together was not 
observed in any of the isolates.  
 
Amplification of ESBL genes  
In the current study, blaTEM was the most prevalent gene 
observed in 92.21% ESBL producing isolates followed 
by blaAmpC and blaCTX-M which was present among 
64.07% and 37.12% isolates respectively. blaSHV was not 
detected in any of the isolates. Among the most common 
uropathogens i.e E.coli and K.pneumoniae, blaTEM was 
amplified in 91.50% and 84% isolates respectively. Also 
among the ESBL producing E.coli, 40.56% isolates 
harboured blaCTX-M and 59.43% isolates harboured 
blaAmpC. Among the ESBL producing K.pneumoniae, 
blaCTX-M and blaAmpC was observed in 28% and 68% 
isolates respectively.  
 
In a similar study, Lim et al. (2009) has reported that 
majority of the ESBL positive isolates from Malaysia 
harbored blaTEM-1(88%) followed by blaCTX-M (20%) and 
blaSHV (8%).
[31]
 Bali et al. (2010) reported blaTEM in 
72.72% of E. coli and 75% of Klebsiella spp., while they 
reported 9.09% and 22.72% production of blaSHV and 
blaCTX-M respectively among clinical isolates in 
Turkey.
[32] 
Yushau et al. (2007), reported prevalence of 
ESBL producers in 9.3% clinical isolates in Kano, 
Nigeria.
[33]
  
 
In a study carried out in a rural district of Rajasthan; of 
the 20 ESBL positive E.coli isolates, 60% harbored 
blaTEM, 55% harbored blaSHV and 80% harbored blaCTX-M 
as detected by PCR, and of the 20 ESBL positive 
Klebsiella spp. isolates 75% harbored blaTEM, 60% 
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harbored blaSHV and 85% harbored blaCTX-M.
[34]
 In 
another study carried out by the same authors in a 
tertiary care hospital in Chandigarh, blaTEM and blaSHV 
was observed in 60% and 72% Klebsiella spp. and 52% 
and 48% E. coli respectively.
[35]
 
 
The high prevalence of blaCTX-M is also reported by Vaida 
et al. (2010) among majority of ESBL producing E. coli 
(96%) and K. pneumoniae (71%).
[36] 
It has been observed 
that blaCTX-M is the most prevalent ESBL-encoding gene 
worldwide and is replacing TEM and SHV types as the 
predominant ESBL gene in many European and Asian 
countries.
[37,38]
  
 
 
Fig: 1. Amplification of blaTEM (742bp) by PCR. 
Lane 1: 100bp ladder; Lane 2-12: Genes amplified from 
E.coli isolates 20, 23, 32, 35, 39, 51, 63, 83, 84, 87 and 
94 respectively 
 
 
Fig:2. Amplification of blaCTX-M (413bp) by PCR. 
Lane 1: 100bp ladder; Lane 2-5: genes amplified from 
C.diversus isolates 15, 28, 30 and 58 respectively; Lane 
6-10: genes amplified from E.coli isolates 79, 83, 87, 96 
and 115 respectively. 
 
Fig: 3 Amplification of blaAmpC (346bp) by PCR. 
Lane 1: 100bp ladder; Lane 2-10: Genes amplified from 
E.coli isolates 20, 23, 32, 35, 39, 51, 63, 84, 94 
respectively. 
 
 
Fig 4. Amplification of blaInt1 (180bp) by PCR. 
Lane 1: 100bp ladder; Lane 2-12: genes amplified from 
C.diversus isolates 15, 28, 30, 58, 102, 116, 120, 124, 
497, 500 and 644 respectively. 
 
 
Fig 5. Amplification of blaInt2 (287bp) by PCR. 
Lane 1: 100bp ladder; Lane 2-10: genes amplified from 
E.coli isolates 79, 83, 87, 148, 190, 220, 238, 245, 249 
respectively; Lane 11: genes amplified from 
K.pneumoniae isolate 730. 
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Kiratisin et al. (2008) has also reported increasing trends 
in the prevalence of CTX-M ESBLs. They reported that 
the prevalence of blaCTX-M was strikingly high in their 
study with 99.2% of ESBL-producing K. pneumoniae 
carrying the same.
[39]
  
 
In contrast to these findings where blaCTX-M was found to 
be the most prevalent gene, our study showed blaTEM to 
be the most prevalent gene among E.coli, K.pneumoniae 
as well as other ESBL producing Enteriobacteriacea. The 
difference in our findings may be explained by the fact 
that the epidemiology of antibiotic resistant bacteria 
varies from region to region and from one infection type 
to another. It also differs from one year to another.
[40]
 It 
is for this reason that no two studies show similar 
prevalence of resistance genes if carried out at different 
time periods at different locations, and hence constant 
monitoring of antibiotic resistance is required. 
 
Variations in the prevalence of other ESBL genes have 
been reported worldwide. Molecular analysis of ESBL 
genes carried out by Zaniani et al. (2012) at Mashhad 
University of Medical Sciences, Iran revealed presence 
of 20.6% blaTEM and 14.4% blaSHV type ESBL producers 
in their study.
[41]
 Another study carried out by Anago et 
al. (2015) reported 77.4% blaTEM and 20.2% blaSHV 
producing E.coli in a tertiary care centre in Cotonou, 
Benin.
[42] 
Ahmed et al. (2013) reported 10% isolates to 
carry blaSHV and 53.3% isolates to carry blaCTX-M in a 
tertiary care hospital in Egypt.
[43] 
Jemima and Verghese, 
2008 performed multiplex PCR for detection of blaCTX-M 
and blaSHV from 62 ESBL producing Klebsiella spp. 
Results showed presence of blaSHV in 45% and blaCTX-M 
in 40% clinical isolates of Klebsiella spp.
[44]
  
 
Co-production of Multiple ESBL genes 
In the present study, it has been observed that 37/167 
(22.15%) isolates carried more than one ESBL genes i.e 
blaTEM + blaCTX-M (Table 5). Presence of multiple 
resistance genes allow the pathogen to exhibit resistance 
to more than one or, similar group of antibiotics resulting 
in more serious infections. This is a matter of great 
concern, especially because of the fact that dissemination 
of β­lactamase producing strains are commonly observed 
in hospitals as well as community settings due to 
presence of these resistance determinants on mobile 
genetic elements like plasmids and transposons. Hence if 
detection of ESBL producers is not routinely carried out 
in hospitals (which are the scenario in most of the 
healthcare centres), the occurrence as well as 
dissemination of these resistance factors remain 
undetected and hence, the pathogens are more likely to 
acquire multiple resistant determinants in the form of 
plasmids or, by vertical transfer of genetic 
information.
[45,46]
 
 
In a study carried out by Goyal et al. (2009), majority of 
strains (57.3%) harbored 2 or more ESBL genes,
[47]
 
while Bali et al. (2010) observed that 19.2% ESBL 
isolates carried more than one type of β-lactamase 
genes.
[32]
 In another study by Sharma et al. (2013), it has 
been observed that 31 out of 40 (77.5%) isolates carried 
more than one type of β-lactamase genes with 13 
(32.5%) isolates harboring all the three β-lactamase 
genes (blaTEM, blaCTX-M and blaSHV), 9 (22.5%) isolates 
harboring blaTEM and blaCTX-M, 6 (15%) isolates 
harboring blaSHV and blaCTX-M and 3 (7.5%) isolates 
harboring blaTEM and blaSHV.
[48] 
  
 
A study carried out by Agamy et al. (2009), reported co-
production of blaTEM and blaSHV among 56.8% of the 
isolates, blaTEM and blaCTX-M among 2.27% of isolates, 
blaSHV and blaCTX-M among 9.1% isolates. All three genes 
were detected in 25% of 220 isolates in his study carried 
out in Riyadh, Saudi Arabia.
[49]
 Kaur and Aggarwal, 
(2013) studied 93 phenotypically confirmed ESBL 
producers in their study carried out in North India. The 
molecular characterization revealed that 44.08% isolates 
possessed the blaCTX-M alone, while the blaCTX-M and the 
blaSHV together were found in 20.43% isolates. All three 
genes i.e blaTEM, blaCTX-M and blaSHV were present among 
6.45% isolates.
[50]
 
 
A recent study carried out in Nepal reported co-
production of multiple ESBL genes among 37.5% 
cases.
[51]
 Similar study in Taiwan reported co-existence 
of two or more kinds of ESBL in 40.6% of ESBL 
producing E.coli.
[52]  
 
Table 5: Amplification of ESBL and AmpC genes among uropathogens. 
Pathogens Total ESBL β-lactamase genes  
   
blaTEM blaCTX-M blaAmpC blaInt1 blaInt2 
blaTEM + 
blaCTX-M 
blaTEM/ 
blaCTX-M + 
blaAmpC 
blaTEM + 
blaCTX-M + 
blaAmpC 
E.coli 445 106 99 27 86 10 10 14 80 9 
K.pneumoniae 121 25 24 10 14 10 1 7 16 1 
P.mirabilis 44 4 4 - 4 
 
- - 4 - 
P.vulgaris 15 3 3 3 - 3 - 2 - - 
P.aeruginosa 67 15 13 9 - 15 - 7 3 - 
C.amalonaticus 7 1 1 1 - 1 - 1 - - 
C.diversus 37 11 11 11 4 11 - 6 4 4 
E.aerogenes 1 1 1 - - 1 - - - - 
E.cloacae 1 - - - - - - - - - 
E.fecalis 1 - - - - - - - - - 
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M.morganii 4 - - - - - - - - - 
A.baumanii 4 - - - - - - - - - 
Total 747 167 156 63 108 51 11 37 107 14 
 
Prevalence of Amp-C β-lactamases and its co-
production with ESBL producers 
In the present study, it has been observed that 145/167 
(86.82%) isolates carried more than one type of β-
lactamase genes which is quite high as compared to 
previous studies but in accordance with Sharma et al. 
(2013).
[48] 
Our study further indicated, 14 (8.38%) 
isolates to harbour all three β-lactamase genes (blaTEM, 
blaCTX-M and blaAmpC) (Table 5). AmpC was produced by 
108/167(64.67%) isolates. Co-production of AmpC with 
other β-lactamases was found to be in 107/167 (64.07%) 
isolates. This is an alarmingly high percentage observed 
in our study; the reason being the association of AmpC 
producers with complicated infections and, undetected 
ESBL phenotypes. In a recent study from Punjab, the 
AmpC production was seen in 5.4% isolates.
[53]
 The 
current study shows comparatively high production of 
AmpC among uropathogens in Mumbai. A study carried 
out in Manipal reported a co-production of β-lactamase 
and AmpC among 58.5% E. coli, whereas a study from 
Bangalore reported a co-production rate of 30.1% for E. 
coli and 30.3% for Klebsiella spps.
[54,55]
  
 
To date, AmpC has been found mainly in clinical isolates 
obtained from hospitalized patients.
[56,57]
 Tumbarello et 
al. (2008) has reported more common occurrence of 
AmpC producing E.coli and K.pneumoniae from surgical 
sites. In his study, more than 50% of AmpC 
producing E.coli and K.pneumoniae were isolated from 
surgical sites. In outpatients, the incidence of AmpC 
producing isolates was found among 18.88% E. coli and 
8.33% K. pneumoniae.
[58]  
 
 
Amplification of Integron class 1 and 2  
Integron-borne β-lactamases particularly pose an 
increasing threat to the nosocomial environment, giving 
rise to multi-drug resistant microbes with complex 
resistance patterns. It has become imperative that we 
should continuously strive to understand these complex 
mechanisms of antimicrobial resistance, not only to 
overcome them, but to avoid them from evolving 
further.
[86] 
In our study, class 1 and 2 integrons were 
detected in 51/167 (30.53%) and 11/167(6.58%) isolates 
respectively. Co-production of class 1 and 2 integrase 
genes together was not observed in any of the isolates. 
Table 6 represents the list of ESBL and AmpC producers 
along with co-produced class 1 and 2 integrons. 
 
Table 6: List of ESBL and AmpC producers along with co-produced integrons. 
Sr. No Isolate no. Identified as ESBL genes present Integron FG CF RP 
INTEGRON 1 
1 15 C.diversus CTX-M Int 1 4 (S) ≥256 (R) ≥256 (R) 
2 28 C.diversus TEM, AmpC, CTX-M Int 1 128 (R) ≥256 (R) ≥256 (R) 
3 30 C.diversus TEM, CTX-M Int 1 32 (R) ≥256 (R) ≥256 (R) 
4 58 C.diversus TEM, CTX-M Int 1 4 (S) ≥256 (R) ≥256 (R) 
5 59 C.amalonatus TEM, CTX-M Int 1 4 (S) ≥256 (R) ≥256 (R) 
6 68 K.pneumoniae TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
7 73b E.coli TEM Int 1 16 (R) ≥256 (R) ≥256 (R) 
8 93 P.aeruginosa TEM, CTX-M Int 1 16 (I) ≥256 (R) ≥256 (R) 
9 96 E.coli TEM, CTX-M Int 1 2 (S) ≥256 (R) ≥256 (R) 
10 100 K.pneumoniae TEM, CTX-M Int 1 2 (S) ≥256 (R) 1 (S) 
11 102 C.diversus TEM, AmpC, CTX-M Int 1 ≥256 (R) ≥256 (R) ≥256 (R) 
12 115 E.coli CTX-M Int 1 2 (S) ≥256 (R) ≥256 (R) 
13 116 C.diversus TEM, AmpC, CTX-M Int 1 ≥256 (R) ≥256 (R) ≥256 (R) 
14 120 C.diversus TEM, AmpC, CTX-M Int 1 ≥256 (R) ≥256 (R) ≥256 (R) 
15 123 C.diversus CTX-M Int 1 4 (S) ≥256 (R) ≥256 (R) 
16 124 C.diversus TEM, CTX-M Int 1 4 (S) ≥256 (R) ≥256 (R) 
17 130 P.vulgaris TEM, CTX-M Int 1 4 (S) ≥256 (R) ≥256 (R) 
18 134 P.aeruginosa TEM Int 1 ≥256 (R) ≥256 (R) ≥256 (R) 
19 147 E.coli CTX-M Int 1 2 (S) ≥256 (R) ≥256 (R) 
20 156 P.vulgaris TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
21 160 E.coli TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
22 166 P.vulgaris TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
23 175 P.aeruginosa TEM, CTX-M Int 1 16 (I) ≥256 (R) ≥256 (R) 
24 196 P. aeruginosa TEM, CTX-M Int 1 16 (I) ≥256 (R) ≥256 (R) 
25 202 K.pneumoniae TEM Int 1 ≥256 (R) ≥256 (R) ≥256 (R) 
26 204 E.coli TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
27 208 P.aeruginosa CTX-M Int 1 8 (S) ≥256 (R) ≥256 (R) 
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28 214 P.aeruginosa TEM, CTX-M Int 1 16 ≥256 (R) ≥256 (R) 
29 216 P.aeruginosa TEM, CTX-M Int 1 16 ≥256 (R) ≥256 (R) 
30 227 E.coli TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
31 233 P.aeruginosa TEM, CTX-M Int 1 32 (R) ≥256 (R) ≥256 (R) 
32 234 E.coli TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
33 246 E.coli CTX-M Int 1 2 (S) ≥256 (R) ≥256 (R) 
34 254 E.coli TEM, CTX-M Int 1 4 (S) ≥256 (R) ≥256 (R) 
35 265 P.aeruginosa TEM, CTX-M Int 1 16 (I) 16 (I) 0.5 (S) 
36 271 P.aeruginosa TEM Int 1 ≥256 (R) ≥256 (R) ≥256 (R) 
37 281 P.aeruginosa TEM Int 1 34 (R) ≥256 (R) ≥256 (R) 
38 290 K.pneumoniae CTX-M Int 1 2 (S) ≥256 (R) ≥256 (R) 
39 306 K.pneumoniae TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
40 447 K.pneumoniae TEM, CTX-M Int 1 8 (I) 8 (I) ≥256 (R) 
41 453 K.pneumoniae TEM Int 1 ≥256 (R) ≥256 (R) ≥256 (R) 
42 497 C.diversus TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
43 500 C.diversus TEM, CTX-M Int 1 4 (S) ≥256 (R) ≥256 (R) 
44 536 K.pneumoniae TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
45 593 P.aeruginosa TEM Int 1 ≥256 (R) ≥256 (R) ≥256 (R) 
46 644 C.diversus TEM, CTX-M Int 1 4 (S) ≥256 (R) ≥256 (R) 
47 687 P.aeruginosa TEM Int 1 ≥256 (R) ≥256 (R) ≥256 (R) 
48 741 K.pneumoniae TEM, CTX-M Int 1 8 (I) ≥256 (R) ≥256 (R) 
49 742 P.aeruginosa CTX-M Int 1 2 (S) ≥256 (R) ≥256 (R) 
50 743 P.aeruginosa TEM, CTX-M Int 1 16 (I) ≥256 (R) ≥256 (R) 
51 744 K pneumonia TEM, CTX-M Int 1 32 (R) ≥256 (R) ≥256 (R) 
INTEGRON 2 
52 60 E.aerogenes TEM Int 2 ≥256 (R) ≥256 (R) ≥256 (R) 
53 79 E.coli TEM, CTX-M Int 2 8 (I) ≥256 (R) ≥256 (R) 
54 83 E.coli TEM, CTX-M Int 2 4 (S) ≥256 (R) ≥256 (R) 
55 87 E.coli TEM, CTX-M Int 2 8 (I) ≥256 (R) ≥256 (R) 
56 148 E.coli CTX-M Int 2 2 (S) ≥256 (R) ≥256 (R) 
57 190 E.coli TEM,CTX-M Int 2 8 (I) ≥256 (R) ≥256 (R) 
58 220 E.coli TEM, CTX-M Int 2 4 (S) ≥256 (R) ≥256 (R) 
59 238 E.coli CTX-M Int 2 2 (S) ≥256 (R) ≥256 (R) 
60 245 E.coli TEM, CTX-M Int 2 64 (R) ≥256 (R) ≥256 (R) 
61 249 E.coli TEM Int 2 64 (R) ≥256 (R) ≥256 (R) 
62 730 K.pneumoniae TEM, CTX-M Int 2 8 (I) ≥256 (R) ≥256 (R) 
*FG: Ceftazidime; CF: Cefotaxime; RP: Ceftriaxone; Mer: Meropenem. 
S: sensitive; I: Intermediate; R: Resistant. 
 
All isolates with integrase genes showed ≥256mcg/ml 
MIC for cefotaxime and ceftriaxone except for isolates 
100 (K.pneumoniae), 265 (P.aeruginosa) and 447 
(K.pneumoniae). However, 42 out of the total 62 isolates 
with integron class 1 or 2 genes showed MIC of 
ceftazidime in the sensitive or intermediate range (Table 
6). This may be due to the presence of CTX-M genes in 
all these isolates that confers low degree of resistance 
against ceftazidime. It has been observed that the CTX-
M β-lactamases hydrolyze ceftazidime with a very low 
catalytic efficiency. Thus, CTX-M β-lactamases may 
confer high levels of resistance to cefotaxime and 
ceftriaxone but at the same time exhibit marginal effect 
on the MIC of ceftazidime.
[18]
 The low MIC observed 
towards these antibiotics may also be due to presence of 
porins or other factors that generally lowers the MIC of 
antibiotics against the pathogens.  
 
Class 1 integrons are most prevalent in clinical isolates, 
carrying single or multiple gene cassettes. Integron 
inserted genes encode for various antibiotic resistance 
mechanisms, including over 40 distinct genes, conferring 
resistance towards aminoglycosides, beta-lactams, 
chloramphenicol, macrolides, sulphonamides, antiseptics 
and disinfectants.
[59,28]
  
 
Concerning beta-lactamases, integron-borne gene 
cassettes have been found mainly in P.aeruginosa, 
A.baumannii and various Enterobacteriaceae species 
encompassing Ambler classes A (except TEM and SHV 
types), B and D beta-lactamase enzymes, giving rise to 
widespread β-lactam resistance.[60,18] 
 
Table 7 represents the antibiotic resistance profile of the 
uropathogens harbouring the Integron class 1 or 2. In our 
study, 11 ESBL producing uropathogens were found to 
be resistant to all 24 antibiotics screened. All these 
isolates showed presence of class 1 or 2 integrons. High 
degree of resistance was also observed towards other β-
lactam as well as non-beta lactam antibiotics. Leverstein 
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et al. (2002) has also reported the presence of an integron 
to be significantly associated with multidrug resistance 
where 10 of the 11 isolates were resistant to ampicillin, 8 
were resistant to trimethoprim, 2 were resistant to 
amoxicillin-clavulanic acid, 2 were resistant to 
cefuroxime, and 1 was resistant to gentamicin.
[61]
 
 
Although integrons are considered to be natural 
expression vectors, great variability of the expression 
level of integrated gene cassettes is exhibited. This 
variability is linked to the intrinsic structures of both 
gene cassettes and integrons.
[62] 
Gene expression in an 
integron is dependent on various factors including 
promoter strength, gene copy number, the relative 
distance of the gene cassette from the promoter, and the 
presence of additional internal promoters.
[28,59]
 
Expression is usually mediated via a common promoter 
situated upstream (5` end) of gene cassettes, rather than 
through individual promoters. Higher levels of gene 
expression can be achieved if a second promoter is 
included adjacent to the first, or if the gene in question is 
included as multiple copies.
[63]
 The relative distance 
between a gene cassette and the promoter plays a 
significant role regarding expression, proximal genes 
tend to be expressed more effectively than distal genes. 
As a result distal genes may be poorly expressed and 
have very little effect on the susceptibility of the host 
bacterium to relevant antibiotics.
[28, 59] 
This explains the 
variability of antibiotic resistance profile observed 
among the test pathogens in our study. 
 
Table 7: Antibiotic resistance profile of integron harbouring uropathogens. 
Sr. No Isolate no. Identified as ESBL genes 
Antibiotic resistance profile 
Sensitive Intermediate Resistance 
INTEGRON 1 
1 15 C.diversus CTX-M GM, CH, BA, AS, AK 
CF, PC,RC, CI, TE, ZN, GF, TT, 
OX, RP, ZX, CB, NA, NX, AG, CU, 
CP, FG, PB 
2 28 C.diversus 
TEM, AmpC, 
CTX-M 
AS, CH, CI, GM, 
AK 
CF, 
BA, CF, PC, RC, ZN, GF, TT, OX, 
RP, ZX, NA, NX, AG, CU, PB 
3 30 C.diversus TEM, CTX-M GM, AK, GF 
 
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
4 58 C.diversus TEM, CTX-M AS, BA, CH AK 
CF, PC, RC, CI, TE, ZN, GM, GF, 
TT, OX, RP, ZX, CB, NA, NX, AG, 
CU, CP, FG, PB 
5 59 C.amalonatus TEM, CTX-M 
PB, BA, CH, RC, 
ZN, AK, GF  
AS, CF, PC, CI, TE, GM, TT, OX, 
RP, ZX, CB, NA, NX, AG, CU, CP, 
FG 
6 68 K.pneumoniae TEM, CTX-M 
 
OX, TE 
AS, BA, CF, PC, CH,RC, CI,  ZN, 
GM, AK, GF, TT,  RP, ZX, CB, NA, 
NX, AG, CU, CP, FG, PB 
7 73b E.coli TEM 
ZN, GM, CH, 
AS, 
RC, AK 
BA, CF, PC, CI, TE, GF, TT, OX, 
RP, ZX, CB, NA, NX, AG, CU, CP, 
FG, PB 
8 93 P.aeruginosa TEM, CTX-M CH, AK, GF 
 
AS, BA, CF, PC, RC, CI, TE, ZN, 
GM, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
9 96 E.coli TEM, CTX-M TE, AK 
 
AS, BA, CF, PC, CH,RC, CI, ZN, 
GM, GF, TT, OX, RP, ZX, CB, NA, 
NX, AG, CU, CP, FG, PB 
10 100 K.pneumoniae TEM, CTX-M 
AS, BA, CH, RC, 
TE 
CI, CF 
CF, PC, ZN, GM, AK, GF, TT, OX, 
RP, ZX, CB, NA, NX, AG, CU, CP, 
FG, PB 
11 102 C.diversus 
TEM, AmpC, 
CTX-M 
CH, AK AS 
BA, CF, PC, CI, TE,  GM, GF, TT, 
OX, RP, ZX, CB, NA, NX, AG,  CP, 
FG, 
12 115 E.coli CTX-M CH, GM AS, CF, AK 
BA, PC,RC, CI, TE, ZN, GF, TT, 
OX, RP, ZX, CB, NA, NX, AG, CU, 
CP, FG, PB 
13 116 C.diversus 
TEM, AmpC, 
CTX-M 
AS, BA, CH 
 
CF, PC,RC, CI, TE, ZN, GM, AK, 
GF, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
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14 120 C.diversus 
TEM, AmpC, 
CTX-M 
AS, CH, GM, 
AK, GF 
ZN 
BA, CF, PC, RC, CI, TE, TT, OX, 
RP, ZX, CB, NA, NX, AG, CU, CP, 
FG, PB 
15 123 C.diversus CTX-M AG, FG TT, CF 
AS, BA, PC, CH, RC, CI, TE, ZN, 
GM, AK, GF, OX, RP, ZX, CB, NA, 
NX, CU, CP, PB 
16 124 C.diversus TEM, CTX-M 
 
PB, CL, TE 
AS, BA, CF, PC, CH, CI, TE, ZN, 
GM, AK, GF, TT, OX, RP, ZX, CB, 
NA, NX, AG, CU, CP, FG, PB 
17 130 P.vulgaris TEM, CTX-M 
OX, BA, PC, CI, 
TE, GM, AK, GF 
AS 
CF, CH,RC, ZN, TT, RP, ZX, CB, 
NA, NX, AG, CU, CP, FG, PB 
18 134 P.aeruginosa TEM AK 
OX, AS, GM, 
GF, TE 
BA, CF, PC, CH,RC, CI, ZN, TT, 
RP, ZX, CB, NA, NX, AG, CU, CP, 
FG, PB 
19 147 E.coli CTX-M AK, GF 
 
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM,TT, OX, RP, ZX, CB, NA, 
NX, AG, CU, CP, FG, PB 
20 156 P.vulgaris TEM, CTX-M 
NX, AS, GM, 
AK 
TT, RP, PC, 
RC, GF 
BA, CF, CH, CI, TE, ZN, OX, ZX, 
CB, NA, AG, CU, CP, FG, PB 
21 160 E.coli TEM, CTX-M 
ZX, AS, BA, CH, 
ZN, GM, AK, 
GF 
CU, FG 
CF, PC, RC, CI, TE, TT, OX, RP, 
CB, NA, NX, AG,  CP, PB 
22 166 P.vulgaris TEM, CTX-M 
OX, BA, CH, 
TE, AK, GF 
ZN, GM, PB 
AS, CF, PC, RC, CI, TT, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG 
23 175 P.aeruginosa TEM, CTX-M 
OX, CH, CP, TE, 
AK, GF 
PB, ZN 
AS, BA, CF, PC, RC, CI, GM, TT, 
RP, ZX, CB, NA, NX, AG, CU, FG 
24 196 P. aeruginosa TEM, CTX-M TE, AK, AG 
TT,OX, NA, 
RC, GF 
AS, BA, CF, PC, CH, CI,  ZN, GM, 
RP, ZX, CB,  NX,  CU, CP, FG, PB 
25 202 K.pneumoniae TEM 
RP, ZX, CB, CP, 
CH, AK 
OX, CF, GM, 
GF 
AS, BA, PC, RC, CI, TE, ZN,  TT,  
NA, NX, AG, CU, FG, PB 
26 204 E.coli TEM, CTX-M   
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
27 208 P.aeruginosa CTX-M   
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
28 214 P.aeruginosa TEM, CTX-M 
  
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
29 216 P.aeruginosa TEM, CTX-M 
 
PB 
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG 
30 227 E.coli TEM, CTX-M GM, AK, GF PB 
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG 
31 233 P.aeruginosa TEM, CTX-M ZX, CU, PC 
CP, CH, AK, 
GF 
AS, BA, CF,  RC, CI, TE, ZN, GM,   
TT, OX, RP,  CB, NA, NX, AG,   
FG, PB 
32 234 E.coli TEM, CTX-M CH, GF GM 
AS, BA, CF, PC, RC, CI, TE, ZN, 
AK, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
33 246 E.coli CTX-M CH, GF AK 
AS, BA, CF, PC, RC, CI, TE, ZN, 
GM, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
34 254 E.coli TEM, CTX-M CH, AK ZX 
AS, BA, CF, PC,RC, CI, TE, ZN, 
GM, GF, TT, OX, RP, CB, NA, NX, 
AG, CU, CP, FG, PB 
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35 265 P.aeruginosa TEM, CTX-M 
 
CH, RC, GF 
AS, BA, CF, PC, CI, TE, ZN, GM, 
AK, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
36 271 P.aeruginosa TEM OX, TE ZN, GF 
AS, BA, CF, PC, CH,RC, CI, GM, 
AK, TT, RP, ZX, CB, NA, NX, AG, 
CU, CP, FG, PB 
37 281 P.aeruginosa TEM 
  
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
38 290 K.pneumoniae CTX-M BA, CH AK, GF 
AS,  CF, PC, RC, CI, TE, ZN, GM, 
TT, OX, RP, ZX, CB, NA, NX, AG, 
CU, CP, FG, PB 
39 306 K.pneumoniae TEM, CTX-M CH AK 
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
40 447 K.pneumoniae TEM, CTX-M 
  
TT, OX, RP, ZX, CB. NA, NX, AG, 
CU, CP, FG, PB, AS, BA, CF, PC, 
CH, RC, CI, TE, ZN, GM, AK, GF 
41 453 K.pneumoniae TEM AK PC, RC 
AS, BA, CF, CH, CI, TE, ZN, GM, 
GF, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
42 497 C.diversus TEM, CTX-M 
 
OX, TE 
AS, BA, CF, PC, CH,RC, CI,  ZN, 
GM, AK, GF, TT,  RP, ZX, CB, NA, 
NX, AG, CU, CP, FG, PB 
43 500 C.diversus TEM, CTX-M ZN, AK, GF 
NX, CU, CP, 
PB, AS, CF, 
RC, GM 
BA, PC, CH, CI, TE, TT, OX, RP, 
ZX, CB, NA, AG, FG 
44 536 K.pneumoniae TEM, CTX-M TT, NA, AG, FG OX, CU, CP 
RP, ZX, CB, NX, PB, AS, BA, CF, 
PC, CH, RC, CI, TE, ZN, GM, AK, 
GF 
45 593 P.aeruginosa TEM 
  
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
46 644 C.diversus TEM, CTX-M 
AS, CH, ZN, 
AK, GF  
BA, CF, CH, RC, CI, TE, TT, OX, 
RP, ZX, CB, NA, NX, AG, CU, CP, 
FG, PB 
47 687 P.aeruginosa TEM CH, AK, GF 
 
AS, BA, CF, PC, RC, CI, TE, ZN, 
GM, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
48 741 K.pneumoniae TEM, CTX-M 
  
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
49 742 P.aeruginosa CTX-M 
  
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
50 743 P.aeruginosa TEM, CTX-M 
  
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
51 744 K pneumonia TEM, CTX-M 
  
AS, BA, CF, PC, CH,RC, CI, ZN, 
GM, AK, GF, TT, OX, RP, ZX, CB, 
NA, NX, AG, CU, CP, FG, PB 
INTEGRON 2 
52 60 E.aerogenes TEM AS, CH RC 
BA, CF, PC, CI, TE, ZN, GM, AK, 
GF, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
53 79 E.coli TEM, CTX-M AS, AK, GM 
 
BA, CF, PC, CH,RC, CI, TE, ZN, 
GF, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
54 83 E.coli TEM, CTX-M AS, AK, GM 
 
BA, CF, PC, CH,RC, CI, TE, ZN, 
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GF, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
55 87 E.coli TEM, CTX-M AS, CH, GM AK 
BA, CF, PC,RC, CI, TE, ZN, GF, 
TT, OX, RP, ZX, CB, NA, NX, AG, 
CU, CP, FG, PB 
56 148 E.coli CTX-M 
OX, AS, GM, 
AK, GF 
ZN, TE, CI, 
RC, CF 
BA, PC, CH, TT, RP, ZX, CB, NA, 
NX, AG, CU, CP, FG, PB 
57 190 E.coli TEM,CTX-M AS, AK, GF 
 
BA, CF, PC, CH,RC, CI, TE, ZN, 
GM, TT, OX, RP, ZX, CB, NA, NX, 
AG, CU, CP, FG, PB 
58 220 E.coli TEM, CTX-M AS, CH, AK, GF ZN, 
BA, CF, PC, RC, CI, TE, GM, TT, 
OX, RP, ZX, CB, NA, NX, AG, CU, 
CP, FG, PB 
59 238 E.coli CTX-M GF 
 
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, TT, OX, RP, ZX, CB, 
NA, NX, AG, CU, CP, FG, PB 
60 245 E.coli TEM, CTX-M CH, AK, GF PC 
AS, BA, CF, RC, CI, TE, ZN, GM, 
TT, OX, RP, ZX, CB, NA, NX, AG, 
CU, CP, FG, PB 
61 249 E.coli TEM CH, AK 
 
AS, BA, CF, PC,RC, CI, TE, ZN, 
GM, GF, TT, OX, RP, ZX, CB, NA, 
NX, AG, CU, CP, FG, PB 
62 730 K.pneumoniae TEM, CTX-M 
  
AS, BA, CF, PC, CH,RC, CI, TE, 
ZN, GM, AK, GF, TT, OX, RP, ZX, 
CB, NA, NX, AG, CU, CP, FG, PB 
 
Integron carriage of resistance gene cassettes by the host 
bacterium is found to be dependent on the environment 
that the host organism may be proliferated and, loss of 
integron-borne resistance genes is observed in the 
absence of antibiotic selective pressure.
[63]
 
 
In the current study, 30.53% and 6.58% ESBL producers 
carried class 1 and 2 integrons respectively. Another 
study carried out in a tertiary care hospital in Tehran 
reported 44% of the ESBL positive isolates to carry class 
1 integrons. Also, 6% isolates were found to harbour 
class 2 integrons. They also found a significant 
association between integron carriage and higher rates of 
resistance to β-lactams and other group of antibiotics.[64] 
Similar study carried out at Institute of medical sciences, 
Varanasi, reported presence of class 1 and 2 integrons 
among 82% and 9% ESBL producers respectively.
[65]
 A 
two decade long surveillance study carried out by Yu et 
al. (2003) reported 54.6% ESBL producing uropathogens 
to carry class 1 integron in Korean hospitals. They 
further indicated that the gene cassettes of these 
uropathogens were continuously changed based on 
antibiotic selective pressure; and their sizes were 
increased by the introduction of new cassette genes 
during the two decades of study. The location of 
integrons in plasmids may have contributed to the 
horizontal dissemination of antibiotic resistance gene 
cassettes. Furthermore, antibiotic resistance genes and 
gene cassettes associated with metabolites were both 
introduced into class 1 integrons.
[66]
  
 
Machado et al. (2005), indicated in their study, that the 
selection and spread of genetic elements encoding ESBL 
has no major role for integron dispersal, except 
when blaESBL genes are within an integron platform, such 
as blaCTX-M-9.
[67]
 In addition, the contribution of integrons 
to ESBL dissemination seems to be of small significance, 
as the encoded resistances correspond to old antibiotics 
without significant intensity of selective pressure in the 
current clinical setting. They however, proposed that this 
situation might eventually change, following possible 
events of selection of specific broad-spectrum plasmids 
able to capture integrons,
[68,69]
 or by integron capture of 
determinants encoding resistances to antibiotics 
frequently used in the hospital environment.
[70] 
Surveillance of the integron content of nosocomial E. 
coli populations may be critical to predict and prevent 
the spread of particular antibiotic resistance 
determinants. 
 
REFERENCES 
1. Nickel JC. Urinary Tract Infections and Resistant 
Bacteria: Highlights of a Symposium at the 
Combined Meeting of the 25th International 
Congress of Chemotherapy (ICC) and the 17th 
European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), March 31-April 3, 
2007, Munich, Germany. Reviews in Urology, 2007; 
9(2): 78-80. 
2. Gonzalez C, Schaeffer A. Treatment of urinary tract 
infection: What’s old, what’s new, and what works. 
World J Urol, 1999; 17(6): 372-82. 
3. Johansen TE, Cek M, Naber K, Stratchounski L, 
Svendsen M, Tenke P. Prevalence of hospital 
acquired urinary tract infections in urology 
departments. Eur Urol, 2007; 51(4): 1100-12. 
4. Gastmeier P, Kampf G, Wischnewski N, Hauer T, 
Schulgen G, Schumacher M, Daschener F, Ruden H. 
Aruna et al.                                                                     European Journal of Biomedical and Pharmaceutical Sciences 
 
www.ejbps.com 
 
 
389 
Prevalence of nosocomial infections in 
representative German hospitals. J Hosp Infect, 
1998; 38(1): 37-49. 
5. Magill SS, Edwards JR, Bamberg W, Beldavs WG, 
Dumyati G, Kainer MA, Lynfield R, Malony M, 
Hollod LM, Nadle J, Ray SM, Thompson DL, 
Wilson LE, Fridkin SK. Multistate Point- Prevalence 
Survey of Healthcare associated Infections. N Engl J 
Med, 2014; 370(13): 1198-208. 
6. Kalra OP, Agarwal NK, Sharma SK, Sakhuja V, 
Chugh KS. Acute bacterial prostatitis with giant 
prostatic abscess. Indian J Nephrol, 2002; 12: 88-9. 
7. Sinha N, Agarwal J, Srivastava S, Singh M. 
Analysis of carbapenem-resistant Acinetobacter 
from a tertiary care setting in North India. Indian J 
Med Microbiol, 2013; 31(1): 60-3. 
8. Chandran SP, Nagaraj S, Kalal BS, Muralidharan S, 
Macaden R. In-vitro susceptibility to colistin and 
tigecycline in New Delhi metallo-beta-lactamase-1 
producing Enterobacteriaceae. Indian J Med 
Microbiol, 2013; 31(4): 419-20. 
9. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical 
and Economic Impact of Common Multidrug-
Resistant Gram-Negative Bacilli. Antimicrob 
Agents Chemother, 2008; 52(3): 813-21. 
10. Rao S. Extended-spectrum beta-lactamases. 2012. 
www.microrao.com. 
11. Sougakoff W, Goussard S, Gerbaud G, Courvalin P. 
Plasmid-mediated resistance to third- generation 
cephalosporins caused by point mutations in TEM-
type penicillinase genes. Rev Infect Dis, 1988; 
10(4): 879-84. 
12. Mary VJ, Kandathi AJ, Balaji V. Comparison of the 
methods for the detection of the carbapenamase and 
the metallo- β-lactamases production in the clinical 
isolates. Ind J Med Res, 2005; 121(6): 780-83. 
13. Bush K. Proliferation and significance of clinically 
relevant β-lactamases. Ann N Y Acad Sci, 2013; 
1277: 84-90. 
14. K. Aruna and Tariq M. Prevalance of extended 
spectrum beta-lactamase production among 
uropathogens in South Mumbai and its antibiogram 
pattern. EXCLI, 2012; 11: 363-72. 
15. CLSI. Performance standards for antimicrobial disc 
susceptibility tests, 31(1): CLSI 2011; document 
M100-S21.   
16. Sambrook J, Fritsch EF, Maniatis T. Molecular 
Cloning: a Laboratory Manual, 2
nd
 edn. Cold Spring 
Harbor, NY: Cold Spring Harbor Laboratory, 1986. 
17. Tariq M, Aruna K. Phenotypic and Molecular 
characterization of MBL genes among uropathogens 
isolated in Mumbai city. BMRJ, 2015; 5(4): 368-83. 
18. Poirel L, Naas T, Le Thomas I, Karim A, Bingen E, 
Nordmann P. CTX-M-Type Extended-Spectrum β-
Lactamase that hydrolyzes ceftazidime through a 
single amino acid  substitution in the omega loop. 
Antimicrob Agents Chemother, 2001; 45(12):    
3355-61.  
19. Whichard JM, Joyce K, Fey PD, Nelson JM, Angulo 
FJ, Barrett TJ. β-Lactam Resistance and 
Enterobacteriaceae, United States. Emerg Inf Dis., 
2005; 11(9): 1464-66.  
20. Marchou B, Bellido F, Charnas R, Lucain C, 
Pechère JC. Contribution of beta-lactamase 
hydrolysis and outer membrane permeability to 
ceftriaxone resistance in Enterobacter cloacae. 
Antimicrob Agents Chemother, 1987; 31(10):    
1589-95. 
21. Welsh KJ, Barlow M, Tenover FC, Biddle JW, 
Rasheed JK, Clark LA, McGowan JE. Experimental 
prediction of the evolution of ceftazidime resistance 
in the CTX-M-2 extended-spectrum beta-lactamase. 
Antimicrob Agents Chemother, 2005; 49(3): 1242-4. 
22. Mavroidi A, Tzelepi E, Tsakris A, Miriagou V, 
Sofianou D, Tzouvelekis LS. An integron-associated 
b-lactamase (IBC- 2) from Pseudomonas aeruginosa 
is a variant of the extended spectrum β-lactamase 
IBC-1. J. Antimicrob Chemother, 2001; 48(5):    
627-30. 
23. Jain A, Mondal R. Detection of extended spectrum 
β-lactamase production in clinical isolates of 
Klebsiella spp. Indian J Med Res, 2008; 127(4): 
344-6. 
24. Brun-Buisson C, Philippon A, Ansquer M, Legrand 
P, Montravers F, Duval J. Transferable enzymatic 
resistance to third-generation cephalosporins during 
nosocomial outbreak of multi-resistant Klebsiella 
pneumoniae. Lancet, 1987; 2(8554): 302-6. 
25. Vu H, Nikaido H. Role of beta-lactam hydrolysis in 
the mechanism of resistance of a beta-lactamase-
constitutive Enterobacter cloacae strain to 
Expanded-spectrum beta-lactams. Antimicrob 
Agents Chemother, 1985; 27(3): 393-8. 
26. Queenan AM, Shang W, Bush K, Flamm RK. 
Differential selection of single-step AmpC or efflux 
mutants of Pseudomonas aeruginosa by using 
cefepime, ceftazidime or ceftobiprole. Antimicrob 
Agents Chemother, 2010; 54(10): 4092-7.  
27. Henrichfreise B, Wiegand I, Pfister W, Wiedemann 
B. Resistance mechanisms of 
multiresistant Pseudomonas aeruginosa strains from 
Germany and correlation with hypermutation. 
Antimicrob Agents Chemother, 2007; 51(11):    
4062-70. 
28. Martinez FP, Fluit AC, Schmitz FJ, Verhoef J, Jones 
ME. Many class 1 integrons comprise distinct stable 
structures occurring in different species of 
Enterobacteriaceae isolated from widespread 
geographic regions in Europe. Antimicrob Agents 
Chemother, 1999; 43(3): 686-9.  
29. Nikaido H. Outer membrane barrier as a mechanism 
of antimicrobial resistance. Antimicrob Agents 
Chemother, 1989; 33(11): 1831-6. 
30. Rao SP, Rama PS, Gurushanthappa V, Manipura R, 
Srinivasan K. Extended-Spectrum Beta-Lactamases 
Producing Escherichia coli and Klebsiella 
pneumoniae: A Multi-Centric Study Across 
Karnataka. J Lab Physician, 2014; 6(1): 7-13. 
31. Lim KT, Yasin R, Yeo CC, Puthucheary S, Thong 
KL. Characterization of Multidrug Resistant ESBL 
Aruna et al.                                                                     European Journal of Biomedical and Pharmaceutical Sciences 
 
www.ejbps.com 
 
 
390 
producing Escherichia coli isolates from Hospitals in 
Malaysia. J Biomed Biotechnol, 2009; 165637: 10.  
32. Bali EB, Ac KL, Sultan N. Phenotypic and 
molecular characterization of SHV, TEM, CTX-M 
and extended-spectrum-lactamase produced by 
Escherichia coli, Acinetobacter baumannii and 
Klebsiella isolates in a Turkish hospital. African J 
Microbiol Res, 2010; 4(8): 650-4. 
33. Yushau M, Olonitola SO, Aliyu BS. Prevalence of 
Extended-Spectrum β-lactamases (ESBLs) among 
members of the Enterobacteriaceae isolates obtained 
from Mohammed Abdullahi Wase Specialist 
Hospital, Kano, Nigeria. Intern J Pur App Sci, 2007; 
1(3): 42-8. 
34. Sharma J, Ray P, Sharma M. Plasmid profile of 
ESBL producing Gram-negative bacteria and 
correlation with susceptibility to β-lactam drugs. 
Indian J Pathol Microbiol, 2010; 53(1): 83-6. 
35. Sharma J, Sharma M, Ray P. Detection of TEM & 
SHV genes in Escherichia coli & Klebsiella 
pneumoniae isolates in a tertiary care hospital from 
India. Indian J Med Res, 2010; 132: 332-6. 
36. Vaida S, Marius L, Aurelija B, Justas P, Rita P, 
Agne G. Molecular characterization of extended-
spectrum b-lactamase producing Escherichia coli 
and Klebsiella pneumoniae isolates from hospitals in 
Lithuania. J Med Microbiol, 2010; 59(10): 1263-65. 
37. Livermore DM, Canton R, Gniadkowski M, 
Nordmann P, Rossolini GM, Arlet G, Ayala J, 
Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L, 
Woodford N. CTX-M: changing the face of ESBLs 
in Europe. J Antimicrob Chemother, 2007; 59(2): 
165-74. 
38. Bonnet R. Growing group of extended-spectrum 
beta lactamases: the CTX-M enzymes. Antimicrob. 
Agents Chemother, 2004; 48(1): 1-14. 
39. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon 
P. Molecular characterization and epidemiology of 
extended-spectrum- β-lactamase producing 
Escherichia coli and Klebsiella pneumoniae isolates 
causing health care-associated infection in Thailand, 
where the CTX-M family is endemic. Antimicrob 
Agents Chemother, 2008; 52(8): 2818-24. 
40. Wagenlehner FM, Naber KG. Antibiotics and 
Resistance of Uropathogens. EAU update series, 
2004; 2: 125-35. 
41. Zaniani FR, Meshkat Z, Naderi Nasab MN, 
Karamadini MK, Ghazvini K, Rezaee A, Esmaily H, 
Nabaviniya MS, Hoseini MD. The Prevalence of 
TEM and SHV Genes among Extended-Spectrum 
beta-Lactamases Producing Escherichia 
coli and Klebsiella pneumoniae. Iran J Basic Med 
Sc, 2012; 15(1): 654-60. 
42. Anago E, Ayi-Fanou L, Akpovi CD, Hounkpe WB, 
Agassounon D, Tchibozo M, Bankole HS, Sanni A. 
Antibiotic resistance and genotype of beta-lactamase 
producing Escherichia coli in nosocomial infections 
in Cotonou, Benin. Annals Clin Microbiol 
Antimicrob, 2015; 14(1): 5.  
43. Ahmed OI, El Hady SA, Ahmed TM, Ahmed IZ. 
Detection of bla SHV and bla CTX-M genes in 
ESBL producing Klebsiella pneumoniae isolated 
from Egyptian patients with suspected nosocomial 
infections. Egyptian J Med Human Genetics, 2013; 
14(3): 277-83. 
44. Jemima SA, Verghese S. Multiplex PCR for bla 
CTX-M & bla SHV in the extended-spectrum beta 
lactamase (ESBL) producing Gram-negative 
isolates. Indian J Med Res, 2008; 128(3): 313-7. 
45. Singh N, Kaur P, Aggarwal A. Neonatal septicaemia 
by β­lactamases producing multi­resistant organism 
– cause of concern. Int J Basi c Med Sci., 2013; 4:3. 
46. Gajul SV, Mohite ST, Mangalgi SS, Wavare SM, 
Kakad SV. Klebsiella pneumoniae in septicemic 
neonates with special reference to Extended 
Spectrum β­lactamase, AmpC, Metallo β­lactamase 
production and multiple drug resistance in tertiary 
care hospital. J Lab Physicians, 2015; 7(1): 32-37. 
47. Goyal A, Prasad KN, Prasad A, Gupta S, Ghoshal U, 
Ayyagari A. Extended spectrum beta-lactamases in 
Escherichia coli & Klebsiella pneumoniae & 
associated risk factors. Indian J Med Res., 2009; 
129(6): 695-700. 
48. Sharma M, Pathak S, Srivastava P. Prevalence and 
antibiogram of Extended Spectrum β-Lactamase 
(ESBL) producing Gram negative bacilli and further 
molecular characterization of ESBL producing 
Escherichia coli and Klebsiella spp. J Clin Diag 
Res., 2013; 7(10): 2173-7.  
49. Agamy MHM, Shibl AM, Tawfik AF. Prevalence 
and molecular characterization of extended-
spectrum β-lactamase-producing Klebsiella 
pneumoniae in Riyadh, Saudi Arabia. Annals Saudi 
Med., 2009; 29(4): 253-7. 
50. Kaur M, Aggarwal A. Occurrence of the CTX-M, 
SHV and the TEM Genes among the Extended 
Spectrum β-Lactamase Producing Isolates of 
Enterobacteriaceae in a Tertiary Care Hospital of 
North India. J Clin Diagn Res., 2013; 7(4): 642-5.  
51. Pokhrel RH, Thapa B, Kafle R, Shah PK, 
Tribuddharat C. Co-existence of beta-lactamases in 
clinical isolates of Escherichia coli from 
Kathmandu, Nepal. BMC Res Notes, 2014; 7: 694. 
52. Lin CF, Hsu SK, Chen CH, Huang JR, Lo HH. 
Genotypic detection and molecular epidemiology of 
extended-spectrum beta-lactamase-producing 
Escherichia coli and Klebsiella pneumoniae in a 
regional hospital in central Taiwan. J Med 
Microbiol, 2010; 59(6): 665-71. 
53. Oberoi L, Singh N, Sharma P, Aggarwal A. ESBL, 
MBL and Ampc β Lactamases Producing Superbugs 
– Havoc in the Intensive Care Units of Punjab India. 
J Clin Diagn Res., 2013; 7(1): 70-3. 
54. Rudresh SM, Nagarathnamma T. Extended spectrum 
β-lactamase producing Enterobacteriaceae and 
antibiotic co-resistance. Indian J Med Res., 2011; 
133(1): 116-8. 
55. Shobha KL, Ramachandra L, Rao G, Majumder S, 
Rao SP. Extended spectrum beta-lactamases (ESBL) 
Aruna et al.                                                                     European Journal of Biomedical and Pharmaceutical Sciences 
 
www.ejbps.com 
 
 
391 
in gram negative bacilli at a Tertiary Care Hospital. 
J Clin Diagn Res., 2009; 3: 1307-12. 
56. Corvec S, Crémet L, Leprince C, Dauvergne S, 
Reynaud A, Lepelletier D, Caroff N. Epidemiology 
of Escherichia coli clinical isolates producing AmpC 
plasmidic beta-lactamase during a 5-year period in a 
French teaching Hospital. Diagn Microbiol Infect 
Dis, 2010; 67(3): 277-81. 
57. Voets GM, Platteel TN, Fluit AC, Scharringa J, 
Schapendonk CM, Stuart JC, Bonten MJ, 
Leverstein-van Hall MA; National ESBL 
Surveillance Working Group. Population 
distribution of Beta-lactamase conferring resistance 
to third-generation cephalosporins in human clinical 
Enterobacteriaceae in the Netherlands. PLoS One, 
2012; 7(12): 52102.  
58. Tumbarello M, Sali M, Trecarichi EM, Leone F, 
Rossi M, Fiori B, De Pascale G, D'Inzeo T, 
Sanguinetti M, Fadda G, Cauda R, Spanu T. 
Bloodstream infections caused by extended-
spectrum-beta-lactamase- producing Escherichia 
coli: risk factors for inadequate initial antimicrobial 
therapy. Antimicrob Agents Chemother, 2008; 
52(9): 3244-52. 
59. Martinez FP, Fluit AC, Schmitz FJ, Grek VS, 
Verhoef J, Jones ME. Class 1 integrons in Gram-
negative isolates and association with decreased 
susceptibility to multiple antibiotic compounds. J 
Antimicrob Chemother, 1998; 42(6): 689-96. 
60. Chu YW, Afzal-Shah M, Houang ET, Palepou MI, 
Lyon DJ, Woodford N, Livermore DM. IMP-4, a 
novel metallo-beta-lactamase from nosocomial 
Acinetobacter spp. collected in Hong Kong between 
1994 and 1998. Antimicrob Agents Chemother, 
2001; 45(3): 710-4. 
61. Leverstein-van Hall MA, Paauw A, Box ATA, Blok 
HEM, Verhoef J, Fluit AC. Presence of Integron-
Associated Resistance in the Community Is 
Widespread and Contributes to Multidrug 
Resistance in the Hospital. J Clin Microbiol, 2002; 
40(8): 3038-40. 
62. Hanau BB, Podglajen I, Casin I, Collatz E. An 
intrinsic control element for translational initiation 
in class 1 integrons. Mol Microbiol, 2002; 44(1): 
119-30. 
63. Rosser SJ, Young HK. Identification and 
characterization of class 1 integrons in bacteria from 
an aquatic environment. J Antimicrob Chemother, 
1999; 44(1): 11-18.  
64. Mobarak QM, Ashayeri-Panah M, Eftekhar F, 
Feizabadi MM. Integron mediated multidrug 
resistance in extended spectrum beta-lactamase 
producing clinical isolates of Klebsiella 
pneumoniae. Braz J Microbiol, 2013; 44(3): 849-54. 
65. Bhattacharjee A, Anupurba S, Guar A, Sen MR. The 
prevalence of inducible AmpC β-lactamase 
producing Pseudomonas aeruginosa in a tertiary care 
hospital in northern India. IJMM, 2008; 26(1):      
89-90. 
66. White PA, McIver CJ, Rawlinson WD. Integrons 
and gene cassettes in the Enterobacteriaceae. 
Antimicrob Agents Chemother, 2001; 45(9):      
2658-61.  
67. Machado E, Cantón R, Baquero F, Galán JC, Rollán 
A, Peixe L, Coque TM. Integron Content of 
Extended-Spectrum-β-Lactamase-
Producing Escherichia coli Strains over 12 Years in 
a Single Hospital in Madrid, Spain. Antimicrob 
Agents Chemother, 2005; 49(5): 1823-9. 
68. Carattoli A, Villa L, Pezzella C, Bordi E, Visca 
P. Expanding drug resistance through integron 
acquisition by IncFI plasmids of Salmonella enterica 
Typhimurium. Emerg Infect Dis 2001; 7(3): 444-7. 
69. Sorum H, L'Abée-Lund TM, Solberg A, Wold A. 
Integron-containing IncU R plasmids pRAS1 and 
pAr-32 from the fish pathogen Aeromonas 
salmonicida. Antimicrob Agents Chemother, 2003; 
47(4): 1285-90.  
70. Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, 
Hooper DC. Plasmid-mediated quinolone resistance 
in clinical isolates of Escherichia coli from 
Shanghai, China. Antimicrob Agents Chemother, 
2003; 47(7): 2242-8.  
